Biotech Stocks Healthcare Stocks Small Caps Stocks

Cynata Therapeutics (ASX:CYP) sacks its CEO to stretch A$1.5m past FY27

Cynata Therapeutics (ASX:CYP) has made all staff including the CEO redundant and drawn a A$600k R&D loan to stretch cash beyond FY27.

ByCharlie Youlden

19

Jun 2026

Biotech Stocks Healthcare Stocks Small Caps Stocks

Cynata (ASX:CYP) Phase 3 knee trial misses and Cymerus is now under review

Cynata Therapeutics (ASX:CYP) Phase 3 knee osteoarthritis trial missed both endpoints, triggering a review of the entire Cymerus platform.

ByCharlie Youlden

16

Dec 2025

Biotech Stocks

Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?

Cynata Therapeutics (ASX: CYP) has completed patient enrollment in its Phase 2 clinical trial of a stem cell treatment called CYP-001 for acute graft versus host disease (aGvHD), a potentially…

ByUjjwal Maheshwari

Cynata Therapeutics (ASX:CYP) sacks its CEO to stretch A$1.5m past FY27

Cynata (ASX:CYP) Phase 3 knee trial misses and Cymerus is now under review

Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Cynata Therapeutics (ASX:CYP) sacks its CEO to stretch A$1.5m past FY27

Cynata (ASX:CYP) Phase 3 knee trial misses and Cymerus is now under review

Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here